Goa Therapeutics launches with $15.5M funding to develop fast-acting alcohol sobering drug

Goa Therapeutics announced its launch, backed by $15.5 million raised mainly from individual industry leaders, and has filed for an initial public offering that could raise up to $75 million.

The company's lead candidate, GOA26, is designed to accelerate alcohol metabolism. Goa plans to file an investigational new drug application by the end of the year and start a Phase 1 trial in 2027.

The initial clinical focus is on enabling emergency departments to safely operate on trauma patients with high blood alcohol levels. The long‑term vision is an over‑the‑counter product available in bars, restaurants, vending machines and stores, similar to Narcan.